Andrew Dudum
speaker
1,578 appearances
3 recordings
3 series
first heard Apr 2026
last heard 5 Jul
Andrew Dudum’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 3 in all, peaking in Apr 2026 with 2.
Appearances
And so it was everywhere from a news standpoint.
But the actual strategy and rationale was actually really quite simple.
And the regulatory framework was also really quite simple.
You had a lot of new FDA medications that had come and the demand was through the roof.
So there was, as you said, there was immediate shortages of these medications.
And so we have about a million square feet of infrastructure across the U.S.
and globally where we can compound these medications personalized for patients.
These are regulated 503A, 503B facilities.
The FDA regulates these.
The state boards of pharmacies regulate these facilities.
You have to do exactly what you would do through, you know, CGMC kind of requirements as you would at any other drug manufacturing, right?
Like we hold the same bar of quality.
Yeah, it's essentially pharmacy capabilities to bring active API ingredients, so medications that are approved by the FDA and on very specific lists that you can then combine and adjust in dosage or formulate in new form factors on behalf of the patient.
So you think of one of the simplest examples, and it's not actually compounding, but back in the day, you think of the Flintstone vitamins.
Right.
Kids need their vitamins.
Kids can't swallow pills.
And so the combination of supplements in something that tastes good, that's chewable for a four-year-old, that's like a very simple example of a compounded treatment.
And so with this shortage, this drug shortage—
our facilities from a regulatory standpoint could start manufacturing and producing these medicines, which we did.
Showing 181–200 of 1,578 · page 10 of 79
← Previous
Next →